20-F: IceCure Medical Reports FY2024 Results, Faces Going Concern Uncertainty Amidst Regulatory Review

IceCure Medical's FY2024 annual report reveals ongoing losses and doubts about its ability to continue as a going concern, while awaiting a critical FDA decision on its ProSense system for breast cancer treatment.

Summary

• IceCure Medical's annual report for the fiscal year ended December 31, 2024, indicates a net loss of $15.32 million and accumulated losses of $105.38 million, raising substantial doubt about the company's ability to continue as a going concern.
• The company's plan to address this involves raising funds from existing shareholders and potential investors, but there is no guarantee of success.
• Revenues increased slightly to $3.29 million, with growth in disposables sales offsetting a decrease in system sales.
• The company is awaiting a decision from the FDA regarding its De Novo classification request for the ProSense system for breast cancer indication, expected after the first quarter of 2025.
• A majority of an FDA advisory panel voted favorably on the ProSense system for treating early-stage, low-risk invasive breast cancer.
• The company is also developing its XSense and MSense systems, with regulatory clearance received for XSense in the U.S.
• The company's operations are subject to risks related to financial condition, business and industry, product development, regulatory approval, intellectual property, and Israeli law.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as the FDA advisory panel's vote and regulatory clearance for XSense, the overall sentiment is negative due to the company's financial struggles and going concern uncertainty.

Positives

• Revenues increased to $3.29 million, driven by a 22% increase in disposables sales.
• An FDA advisory panel voted favorably on the ProSense system for treating early-stage, low-risk invasive breast cancer.
• The company received 510(k) regulatory clearance for its XSense system with CryoProbes in the U.S.
• The company is developing its next-generation MSense system for treating multiple and larger tumors.
• The company has regulatory approvals for its systems in 15 countries, including the U.S., Europe, and China.

Negatives

• The company's FY2024 net loss was $15.32 million, with accumulated losses reaching $105.38 million.
• Cash and cash equivalents stood at $7.6 million as of December 31, 2024, deemed insufficient to fund planned operations for the next 12 months.
• The company's management has concluded that there are conditions that raise substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on third-party manufacturers and suppliers, making it vulnerable to supply shortages and problems.
• The company faces intense competition in the market, and may be unable to effectively compete in its industry.

Risks

• The company's ability to continue as a going concern is uncertain due to substantial operating losses and limited revenues.
• The company's success is highly dependent on the successful development, regulatory clearances, and marketing and sale of its ProSense, XSense, and MultiSense systems.
• The company is dependent on third-party manufacturers and suppliers, making it vulnerable to supply shortages and problems.
• The company faces intense competition in the market, and may be unable to effectively compete in its industry.
• The company's business and operations might be adversely affected by security breaches, including any cybersecurity incidents.
• Current and potential political, economic and military instability in Israel may adversely affect the company's results of operations.

Future Outlook

The company expects to continue generating operating losses and will need to raise substantial additional funding to continue operations. The company is focused on obtaining regulatory approval for its existing and next-generation products, expanding its distribution network, and obtaining reimbursement coverage for its products.

Industry Context

The announcement highlights the challenges faced by small medical device companies in a competitive market, particularly in obtaining regulatory approvals and achieving profitability. The company's focus on cryoablation as a minimally invasive alternative to surgery aligns with broader trends in the medical device industry towards less invasive procedures and improved patient outcomes.

Comparison to Industry Standards

• The report mentions Boston Scientific Corporation and Siemens Healthineers as major players in the cancer cryoablation market, indicating the competitive landscape IceCure operates in.
• The report also mentions competing heat base technologies in the thermal ablation sector such as radiofrequency ablation, or RFA, microwave ablation, or MWA, and irreversible electroporation, or high-intensity focused ultrasound which are developed by entities such as NeuWave Medical, Inc., Angiodynamics, and Inisghtec Ltd.

Legal Proceedings

• A motion to certify a claim as a class action was filed against the company in Israel, alleging that the company's reports are not in compliance with applicable accessibility guidelines. The motion was dismissed by the Tel-Aviv Jaffa District Court on March 5, 2023.
• A motion to certify a claim as a class action was filed in Israel against the company, its directors, controlling shareholder, and investors, alleging defects in the private placement approved on March 7, 2021. The company believes the motion is without merit.

Related Party Transactions

• Epoch Partner Investments Limited, a major shareholder, participated in a public offering, purchasing 4,242,424 Ordinary Shares at $1.65 per share.
• Yang Huang, a director, was appointed by Epoch, one of the company's shareholders.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future equity offerings.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
• Customers and patients may benefit from the company's ongoing development of new and improved cryoablation systems.
• The company's suppliers and distributors may be impacted by changes in the company's production and sales volumes.

Next Steps

• The company is awaiting a decision from the FDA regarding its De Novo classification request for the ProSense system for breast cancer indication, expected after the first quarter of 2025.
• The company intends to seek additional regulatory approvals for its products in specific indications and countries.
• The company plans to continue its research and development efforts, particularly for its MSense system.
• The company intends to continue its efforts to obtain regulatory approval for its XSense system with CryoProbes.
• The company intends to expand utilization and use of its products for breast cancer treatment by commercial sales and clinical studies around the world.

Key Dates

Keywords

cryoablation, ProSense, XSense, MSense, FDA, regulatory approval, breast cancer, tumor, medical device, financial results, going concern, ICE3 trial, Terumo, China